12/12/2024 - General information
The SAGITTARIUS clinical trial has officially begun with the inclusion of the first six patients in the project. Among them, the first at the Hospital del Mar, a collaborating center in the study, which is coordinated in Spain by Dr. Clara Montagut, head of the Gastrointestinal Tumors section of the Medical Oncology Service and coordinator of the Colorectal Cancer Precision Medicine Research Group at the Hospital del Mar Research Institute.
Més informació "The SAGITTARIUS clinical trial, led by the Hospital del Mar in Spain, gets underway"
18/11/2024 - Press release
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment. This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors.
13/11/2024 - General information
The "la Caixa" Foundation has selected 29 new high-impact, socially relevant biomedical research projects. One of these projects, led by the Center for Genomic Regulation, includes participation by Dr. Toni Celià-Terrassa, coordinator of the Cancer Stem Cells and Metastasis Dynamics Research Group at the Hospital del Mar Research Institute.
06/11/2024 - Press release
This study will be conducted in collaboration with the Josep Carreras Leukemia Research Institute, and researchers from Finland, the Netherlands, and the United Kingdom will participate. The goal is to develop and validate protocols and systems for generating laboratory-derived stem cells to regenerate patients' blood. The European Research Council, which provides these grants, is the leading funding organization for advanced and excellent research on the continent. It is an organization created by the European Union.
05/06/2024 - Press release
A scientific team led by Dr Anna Bigas, from the Hospital del Mar Research Institute and the Josep Carreras Institute, has described the role of the IκBα protein in the differentiation process of haematopoietic cells. In the absence of this protein, the stem cells enter quiescence, acquire a dormant state and maintain their potential, which may allow them to be transplanted for therapeutic uses in leukaemia or blood diseases of genetic origin. This is an important step towards being able to generate these types of cells in the lab, preventing them from differentiating and turning into other cells too early.
03/05/2024 - Press release
Natural Killer (NK) cells, when exposed to antibody treatment used against HER2-positive breast cancer, secrete specific types of cytokines that activate the immune response against tumor cells. Researchers have confirmed that patients with NK lymphocytes present in the tumor environment show a better response to treatment, thanks to this mechanism. This confirms the feasibility of using cytokines secreted by NK cells as markers of response to anti-HER2 antibodies with a simple blood test. It also reaffirms various clinical trials using these lymphocytes to bolster treatment in patients with metastatic HER2-positive breast cancer.
15/04/2024 - General information
The Reial Acadèmia de Medicina de Catalunya chose, in a plenary session held on April 9, Dr. Manuel Pera as the new full academician of the institution. Dr. Pera, who was already a corresponding academic since 2022, will be attached to the surgery section of the institution. The section chief of the Gastrointestinal Surgery Unit of the Hospital del Mar and researcher at the center's Research Institute, thus becomes one of the sixty full academicians of the institution. The election is made by a vote among the members themselves. The ceremony of entry into the Royal Academy will take place in the coming months.
16/11/2023 - Institutional news
The Universidad Francisco de Victoria (UFV), in association with the science and technology company MERCK, presents awards to researchers who have made significant clinical and scientific contributions in the field of cancer immunology research.
A study involving the Hospital del Mar Research Institute, the Vall d'Hebron Institut d'Oncologia, IDIBELL, and the Institut Català d'Oncologia suggests that combining chemotherapy with drugs that can inhibit two cell signaling pathways involved in tumor progression may aid in treatment. The research has analyzed the interaction of the protein IKKα with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing treatment toxicity. The study opens the door to new approaches for tumors with the presence of this protein. It is published in the EMBO Journal.
Més informació "A possible new combination of treatments to combat cancer"
11/10/2023 - Institutional news
The prizes were awarded at the SEOM congress held in Barcelona at the end of September. The doctoral thesis of Dr. Pedro Rocha, assistant doctor at the Oncology Department of the Hospital del Mar and researcher at the Hospital del Mar Research Institute, has received one of the five grants awarded by the Spanish Society of Medical Oncology (SEOM) to doctoral theses by young researchers. The award ceremony took place on 22 September during the congress of the organisation.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
